about
Experimental support for the evolution of symmetric protein architecture from a simple peptide motifProteinase-activated receptors, targets for kallikrein signalingKallikreins are associated with secondary progressive multiple sclerosis and promote neurodegenerationStructural assembly of the active site in an aldo-keto reductase by NADPH cofactorAccommodation of a highly symmetric core within a symmetric protein superfoldStructural alteration of cofactor specificity in Corynebacterium 2,5-diketo-D-gluconic acid reductaseA structural mechanism for dimeric to tetrameric oligomer conversion inHalomonassp. nucleoside diphosphate kinaseStructure and function of ∆1-tetrahydrocannabinolic acid (THCA) synthase, the enzyme controlling the psychoactivity of Cannabis sativaEvolution and design of protein structure by folding nucleus symmetric expansionMutation choice to eliminate buried free cysteines in protein therapeuticsX-ray crystal structure of human acidic fibroblast growth factorDisordered water within a hydrophobic protein cavity visualized by x-ray crystallographyA comprehensive nomenclature for serine proteases with homology to tissue kallikreinsAnalysis of the dynamics of assembly and structural impact for a histidine tagged FGF1-1.5 nm Au nanoparticle bioconjugate.Structural and energetic consequences of mutations in a solvated hydrophobic cavity.Substrate specificity of human kallikreins 1 and 6 determined by phage display.Functional role of kallikrein 6 in regulating immune cell survival.Kallikrein cascades in traumatic spinal cord injury: in vitro evidence for roles in axonopathy and neuron degeneration.Kallikrein 6 signals through PAR1 and PAR2 to promote neuron injury and exacerbate glutamate neurotoxicity.Substrate specificity of kallikrein-related peptidase 13 activated by salts or glycosaminoglycans and a search for natural substrate candidates.Protein design at the interface of the pre-biotic and biotic worlds.Structural basis for acceptor-substrate recognition of UDP-glucose: anthocyanidin 3-O-glucosyltransferase from Clitoria ternatea.Pharmacokinetic properties of 2nd-generation fibroblast growth factor-1 mutants for therapeutic application.Structural biology of the aldo-keto reductase family of enzymes: catalysis and cofactor binding.Redesigning symmetry-related "mini-core" regions of FGF-1 to increase primary structure symmetry: thermodynamic and functional consequences of structural symmetry.Protease-activated receptor dependent and independent signaling by kallikreins 1 and 6 in CNS neuron and astroglial cell lines.Structural characteristics of alkaline phosphatase from the moderately halophilic bacterium Halomonas sp. 593.Emergence of symmetric protein architecture from a simple peptide motif: evolutionary models.Symmetric protein architecture in protein design: top-down symmetric deconstruction.An S116R Phosphorylation Site Mutation in Human Fibroblast Growth Factor-1 Differentially Affects Mitogenic and Glucose-Lowering Activities.An insight into the thermodynamic characteristics of human thrombopoietin complexation with TN1 antibody.Isomannide-based peptidomimetics as inhibitors for human tissue kallikreins 5 and 7.Kallikrein-mediated cell signalling: targeting proteinase-activated receptors (PARs).Complete nucleotide sequence of the Escherichia coli gene encoding malate dehydrogenasePharmacological Activities and Hydrolysis by Peptidases of [Phospho-Ser(6)]-Bradykinin (pS(6)-BK).Specificity studies on Kallikrein-related peptidase 7 (KLK7) and effects of osmolytes and glycosaminoglycans on its peptidase activity.Prebiotic protein design supports a halophile origin of foldable proteins.An empirical phase diagram approach to investigate conformational stability of "second-generation" functional mutants of acidic fibroblast growth factor-1.Structure of a highly acidic β-lactamase from the moderate halophile Chromohalobacter sp. 560 and the discovery of a Cs(+)-selective binding site.Sequence swapping does not result in conformation swapping for the beta4/beta5 and beta8/beta9 beta-hairpin turns in human acidic fibroblast growth factor.
P50
Q21045395-41F51338-C3CB-43C8-A2D6-0C9ACDF9D200Q24298638-97B1D718-2438-478D-94F9-E5E2C6530736Q24643613-A075AD71-8D3A-49FD-857B-477138059A17Q27632529-57AC5864-CB9B-45E8-9083-4332A006B6CAQ27642593-29E23B17-B88B-42DE-B6E8-EEF788FA83AAQ27642931-DC3E82A3-0796-4B81-90C5-B5F218C18782Q27676865-81AD697D-2E6C-44B8-9FFF-287BEAAB60FCQ27681709-FAEE6494-B9DF-487C-AD62-606F8028586CQ27695631-5A007B87-5123-42A8-95FD-03B2A1C09452Q27695703-5AE1DEC3-4E93-4E04-AFDE-44859AD750B0Q27732790-76A3145C-2679-4FE8-83CA-2C1D2716EDA4Q27766416-89D4001D-40C4-46D6-9807-E656C64C6107Q28248469-B99E4974-B214-45EB-A6C8-7C8EF9673F80Q30381438-45B27BD7-C346-4EA4-AE04-B3C6C3C01DA6Q33211090-530775E3-C6B8-4F4D-9E60-D14EF16B3AA6Q33325124-0D02DB3A-93C2-4E00-B4ED-F8A451F3C803Q33862447-702D735F-752E-49BB-9B4F-8CD227D49646Q33898347-D3979230-61D8-47B1-99BB-046AC3D738CFQ33898352-03B4A704-F139-4946-9EEA-5F3D5B512219Q33937650-EAE1F40D-C691-4568-91CD-A0DFD5776F67Q34286667-7576C533-68FE-4F08-BA6A-8E6B3E4AC99BQ34456409-E4EDC993-5AD2-4DE8-BFEF-6565BAC5D710Q34469627-75CA5C47-8773-4E32-BB44-FE74FD0107F2Q35094128-AE07EFF1-5D00-4DD2-A5CF-C9358145936DQ36477003-7A41A397-DF1F-407B-90C0-307C0F93F176Q37217423-6F5C7A8E-1BAE-4C5F-AD33-8E088A0777FEQ37630128-246BA0D5-AF80-41D9-9A23-E14D609868E6Q38025871-C4CC5832-94A9-4E4E-BA4D-3F82FE7242A8Q38248510-636B1C67-B335-4E55-8ECD-2EE410C3F036Q38290536-9469FFFC-F6FE-41E5-B39C-061FD645FF1EQ39599068-35743CEA-11CD-4E16-9442-E1404EBD9CC6Q39782728-EE927639-09BE-464B-84AD-700BFADE650FQ40262724-61D575FC-B0E0-40CE-9D9C-2E7B15CC504EQ40388773-E228C0CC-F83C-4C08-875A-233BB4790DA8Q40667568-B689AF97-E618-4C66-9A4D-1D1ACCD3FA65Q41757886-D5B6937D-928F-408A-9930-7AB32146C5DBQ41843725-FAE74E7C-8A60-43F4-A9E2-64795784D481Q41905086-41FFE7A4-6B88-49C5-B29F-0A55275A414CQ41908473-4CDDBC38-9008-465D-911E-49797C7B29B0Q41915622-C2C7F210-FCF4-49F1-8FB0-0886BC18C8AB
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Michael Blaber
@ast
Michael Blaber
@en
Michael Blaber
@es
Michael Blaber
@nl
Michael Blaber
@sl
type
label
Michael Blaber
@ast
Michael Blaber
@en
Michael Blaber
@es
Michael Blaber
@nl
Michael Blaber
@sl
prefLabel
Michael Blaber
@ast
Michael Blaber
@en
Michael Blaber
@es
Michael Blaber
@nl
Michael Blaber
@sl
P108
P106
P1153
56262843400
P21
P2798
P31
P3835
michael-blaber
P496
0000-0002-6856-1643